A computational pipeline combining machine learning and molecular simulations identifies repurposed PI3Kα inhibitors from FDA-approved drugs

Puntos clave

• Repurposed PI3Kα inhibitors were identified through a computational pipeline, enhancing drug discovery.
• Machine learning methods revealed potential candidates among FDA-approved drugs, improving efficiency.
• Observational analysis used molecular simulations to evaluate the efficacy of identified inhibitors against PI3Kα.
• Findings suggest that leveraging existing drugs may expedite treatment options for specific conditions.